Review the pathophysiologic/immunogenic molecular drivers of CRS that lead to the inflammatory endotypes and relevant comorbidities frequently observed in patients with CRSwNP
|
|
|
|
|
|
Discuss the differences between currently approved and emerging biologic treatment options for CRSwNP using data from clinical trials and other analyses
|
|
|
|
|
|
Incorporate an individualized, patient-centric focus based on consensus criteria for patients with CRSwNP when recommending a biologic therapy or endoscopic sinus surgery
|
|
|
|
|
|